Verition Fund Management’s Tourmaline Bio TRML Stock Holding History

Verition Fund Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,985	Closed	-$334K	–	3954
2025 Q3	$334K	Sell	6,985 -33,045	-83%	-$916K	﹤0.01%	3244
2025 Q2	$640K	Buy	+40,030	New	+$649K	﹤0.01%	2781

Verition Fund Management's TRML Position: Q4 2025 in Review

Verition Fund Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 6,985 shares — an estimated $334K sold.

Verition Fund Management first reported a position in TRML in Q2 2025 and held it in 2 quarters. The position peaked at $640K in Q2 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Verition Fund Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Verition Fund Management sold 6,985 Tourmaline Bio shares in Q4 2025, an estimated $334K.
Verition Fund Management first reported a position in Tourmaline Bio in Q2 2025 and held it in 2 quarters.
Verition Fund Management's Tourmaline Bio position peaked at $640K in Q2 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.